Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
URLC10-177, TTK-567, and Agatolimod in Esophageal Cancer
NCT00669292Phase 2Unknown
- Sponsor
- Wakayama Medical University
- Start
- Nov 2006
- Primary completion
- Nov 2009
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of LY6K peptide vaccine, TTK-567, agatolimod in esophageal cancer, sponsored by Wakayama Medical University. Status: unknown.
02
Drugs
LY6K peptide vaccineTTK-567agatolimod
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT00669292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00669292.